Brought to you by 
LivaNova enters loan agreement with BoA Merrill Lynch to support TandemLife acquisition
01 Mar 2018
Executive Summary
In connection with its acquisition of cardiopulmonary device firm TandemLife, LivaNova PLC entered into a $170mm term loan facility with Bank of America Merrill Lynch International Ltd. The facility will terminate on August 14, 2018, but can be extended to February 13, 2019 under certain circumstances. The loan bears interest at a variable annual rate based on LIBOR plus an applicable margin of 0.75% per annum for the first six months, 1% for the following three months, and 1.25% after that time. For TandemLife, LivaNova is paying $200mm up front and up to $50mm in regulatory milestones.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LivaNova enters loan agreement with BoA Merrill Lynch to support TandemLife acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice